AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lixisenatide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| peptides and glycopeptides | 4815 | 320367-13-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist that binds GLP-1 receptor that is used to control blood sugar levels in patients with TYPE 2 DIABETES; amino acid sequence is H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSK KKKKK-NH2 (ZP10A).
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | U | P |
| 20 | mcg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 24, 2013 | PMDA | Sanofi K.K. | |
| July 27, 2016 | FDA | SANOFI-AVENTIS US LLC | |
| Feb. 1, 2013 | EMA | Sanofi-Aventis Groupe |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic ketoacidosis | 54.14 | 46.99 | 13 | 190 | 42045 | 110547051 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10AE54 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting |
| ATC | A10BJ03 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues |
| FDA CS | M0160181 | Glucagon-Like Peptide 1 |
| FDA MoA | N0000020058 | Glucagon-like Peptide-1 (GLP-1) Agonists |
| FDA EPC | N0000178480 | GLP-1 Receptor Agonist |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:71196 | glucagon-like peptide-1 receptor agonist |
Related Drugs by ATC class:
A10AE Insulins and analogues for injection, long-acting 9 drugs
A10BJ Glucagon-like peptide-1 (GLP-1) analogues 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.15 | acidic |
| pKa2 | 3.62 | acidic |
| pKa3 | 3.86 | acidic |
| pKa4 | 4.07 | acidic |
| pKa5 | 4.31 | acidic |
| pKa6 | 4.6 | acidic |
| pKa7 | 12.21 | acidic |
| pKa8 | 12.44 | acidic |
| pKa9 | 12.46 | acidic |
| pKa10 | 12.61 | acidic |
| pKa11 | 12.8 | acidic |
| pKa12 | 12.94 | acidic |
| pKa13 | 13.0 | acidic |
| pKa14 | 13.01 | acidic |
| pKa15 | 13.16 | acidic |
| pKa16 | 13.28 | acidic |
| pKa17 | 13.31 | acidic |
| pKa18 | 13.37 | acidic |
| pKa19 | 13.43 | acidic |
| pKa20 | 13.45 | acidic |
| pKa21 | 13.6 | acidic |
| pKa22 | 13.66 | acidic |
| pKa23 | 13.67 | acidic |
| pKa24 | 13.79 | acidic |
| pKa25 | 13.81 | acidic |
| pKa26 | 13.82 | acidic |
| pKa27 | 13.96 | acidic |
| pKa28 | 13.98 | acidic |
| pKa29 | 11.5 | Basic |
| pKa30 | 11.39 | Basic |
| pKa31 | 11.16 | Basic |
| pKa32 | 10.98 | Basic |
| pKa33 | 10.81 | Basic |
| pKa34 | 10.64 | Basic |
| pKa35 | 10.45 | Basic |
| pKa36 | 10.23 | Basic |
| pKa37 | 9.85 | Basic |
| pKa38 | 7.86 | Basic |
| pKa39 | 5.98 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucagon-like peptide 1 receptor | GPCR | AGONIST | IC50 | 8.85 | SCIENTIFIC LITERATURE | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D09729 | KEGG_DRUG |
| 4036289 | VANDF |
| CHEBI:85662 | CHEBI |
| CHEMBL2108336 | ChEMBL_ID |
| C479460 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7387 | IUPHAR_LIGAND_ID |
| DB09265 | DRUGBANK_ID |
| 74O62BB01U | UNII |
| 1440051 | RXNORM |
| 244072 | MMSL |
| 29296 | MMSL |
| d08068 | MMSL |
| 015267 | NDDF |
| 708808004 | SNOMEDCT_US |
| 763570007 | SNOMEDCT_US |
| C2973895 | UMLSCUI |
| 8970 | INN_ID |
| 90472060 | PUBCHEM_CID |
| 74O62BB01U | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Soliqua 100/33 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0024-5761 | INJECTION, SOLUTION | 33 ug | SUBCUTANEOUS | BLA | 34 sections |